cerca CERCA
Mercoledì 28 Settembre 2022
Aggiornato: 22:13
Temi caldi

marketed in India

comunicato stampa

Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India

GAITHERSBURG, Md. and PUNE, India, March 22, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, announced that the Drugs Controller General of India (DCGI) has granted emergency use authorization (EUA) for Novavax' protein-based COVID-19 vaccine for adolescents aged ≥12 to <18...

comunicato stampa

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India

GAITHERSBURG, Md. and PUNE, India, Dec. 28, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, today announced that the Drugs Controller General of India (DCGI) has granted emergency use authorization (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vaccine w...

ora in
Prima pagina
articoli
in Evidenza